Skip to content

One-stage and Delayed Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiopancreatography with Endoscopic Sphincterotomy in Cholecystocholedocholithiasis

One-stage and Delayed Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiopancreatography with Endoscopic Sphincterotomy in Cholecystocholedocholithiasis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06676241
Enrollment
44
Registered
2024-11-06
Start date
2024-11-13
Completion date
2025-03-05
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis (AP), Children, Cholangiopancreatography, Endoscopic Retrograde, Cholecystolithiasis, Choledocholithiasis, Common Bile Duct Calculi, Laparoscopic Cholecystectomy

Keywords

Сholedocholelysis, Endoscopic retrograde cholangiopancreatography (ERCP)

Brief summary

In this study, it is planned to compare ERCP with ES + delayed LC in children, with one-stage LC + ERCP with ES in adults to confirm that ERCP with ES + delayed LC is more suitable for pediatric patients with cholecystocholedocholithiasis.

Detailed description

Nowadays there is no gold standard for the treatment of choledocholithiasis combined with cholecystolithiasis in the pediatric population. The most common method for resolving the biliary obstruction is endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy (EST) and laparoscopic cholecystectomy (LC). In the adult practice, the approaches to the treatment of choledocholithiasis include the following items: laparoscopic common bile duct exploration (LCBDE), laparoendoscopic rendezvous method (LERV) and LC after ERCP. Both LCBDE and LERV allow for the simultaneous treatment of cholecystocholedocholithiasis. However, a great number of medical institutions do not have an opportunity to use these methods due to the difficulties of implementation and the need for special training and experience of specialists. The timing of LC after ERCP in patients with cholecystocholedocholithiasis also remains a subject of debate. Numerous studies recommend early LC after ERCP. However, there are high risks of injury to the common bile duct and hepatic vessels against the background of acute inflammatory process in the area of hepatoduodenal ligament. In this study, it is planned to compare ERCP with ES + delayed LC in children, with one-stage LC + ERCP with ES in adults to confirm that ERCP with ES + delayed LC is more suitable for pediatric patients with cholecystocholedocholithiasis. The aim of this study is to evaluate the efficacy and safety of endoscopic retrograde cholangiopancreatography, endoscopic sphincterotomy with delayed laparoscopic cholecystectomy in children with cholecystocholedocholithiasis compared with one-stage cholangiopancreatography, endoscopic sphincterotomy and laparoscopic cholecystectomy in adults with cholecystocholedocholithiasis.

Interventions

PROCEDUREendoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy

Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.

Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP

Sponsors

Moscow Regional Research and Clinical Institute (MONIKI)
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Informed consent from the patient, child or legal representative * Age 0-80 years * Acute cholecystitis * Choledocholithiasis * Intraoperative ERCP * Preoperative ERCP followed by cholecystectomy

Exclusion criteria

* Unwillingness or inability to consent to the study * Pregnancy * Age \> 80 years * Previous ERCP or percutaneous transhepatic biliary drainage * Anastomosis in the upper gastrointestinal tract * Benign or malignant stricture * Preoperative comorbidities: gastrointestinal bleeding, severe liver disease, acute and chronic cholangitis, other known cholestatic hepatopancreatobiliary disease, septic shock. * In combination with Mirizzi syndrome and intrahepatic bile duct stones * Congenital anomaly of the biliary tract * Malignant neoplasms * Acute pancreatitis

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of stones in the common bile duct30 days after ERCPThe diagnosis of the stone in the common bile duct.

Secondary

MeasureTime frameDescription
Perforation30 days after ERCPby CT, radiography (fluid or gas in the retroperitoneal space or abdominal cavity, visual picture during endoscopic examination)
Bile leak30 days after ERCPbile aspirated from the abdominal cavity
Acute cholangitis60 days after ERCPintermittent chills, fever, increased proinflammatory blood markers after ERCP
Bile duct stricture1 year after ERCPafter ERCP
Bleeding30 days after ERCPdecreased hemoglobin level, visual picture during endoscopic examination, positive stool for occult blood
Technical success - success of the procedures as documented by a yes or no1 month
Duration of the laparoscopic cholecystectomy,minFrom enrollment to the end of treatment (3 month)
Acute pancreatitiswithin 14 days after ERCPat least two out of three criteria according to the classification developed by the INSPPIRE group
Duration of the Endoscopic retrograde cholangiopancreatographyFrom enrollment to the end of treatment (3 month)
Time spent in hospital until dischargefrom admission to hospital until the end of treatment (up to 8 weeks)

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026